Zhimeng Biopharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Clinical-stage biotech developing novel small molecules for functional cure of chronic hepatitis B and treatment of severe neurological disorders.
ImmunologyNeurologyPsychiatryInfectious Disease
Technology Platform
Multi-pronged small molecule platform for HBV targeting nucleocapsid assembly (CAMs), immunomodulation, and RNA destabilization, plus CNS-targeted small molecule discovery.
Opportunities
Large addressable market in China with ~86 million HBV carriers and significant unmet needs in neurological disorders; potential for combination therapies to achieve functional cure for HBV.
Risk Factors
High clinical development risk in both HBV and CNS areas; competitive landscape for HBV functional cure; dependence on funding as a private, pre-revenue company.
Competitive Landscape
Faces competition in HBV from companies like Gilead, Janssen, and Assembly Biosciences; differentiation lies in comprehensive multi-target approach combining direct antivirals with immunomodulators for functional cure.